iPLATO Experiences Strong Support from Clinical Commissioning Groups

iPLATO HealthcareiPLATO, a leader in mHealth and Analytics, reports strong support from CCGs - the new healthcare commissioners in England. Following explosive growth in new patients and primary care practices over the last year the company reports 100% renewal rates for CCGs on iPLATO Enterprise in 2012/13. iPLATO attributes its ability to retain customers to market leading technology and support combined with relentless focus on innovation to improve outcomes.

In addition to high retention rates of our commissioning partners, iPLATO has experienced a stronger long term commitment to mHealth with half of its CCG partners up for renewal over the last six months of the NHS financial year moving from one to three year subscriptions.

"Considering the organisational turmoil when PCTs where abolished and CCGs picked up the commissioning baton, it is remarkable that we renewed every single one of our many CCG partners in 2012/13," said Tobias Alpsten, CEO of iPLATO Healthcare. "For a cloud computing business like ours it is crucial that we hold onto our existing customers year-on-year whilst adding new partners. Clearly, this would not have happened without strong and vocal support from many leading GP practices."

"That fact that half of our CCGs have moved from one to three year contracts is a sign that iPLATO is becoming part of the strategic plans for A&E avoidance, patient engagement and long term condition management. Lead by companies like iPLATO, the use of Analytics to target patients and interventions combined with mHealth as an engagement mechanism is only just beginning to realise its enormous potential."

Related news articles:

About iPLATO
iPLATO Healthcare is British innovation company dedicated to mHealth and Analytics since 2006.

iPLATO's evidence based mobile health solutions have proven to improve patient access to healthcare, to enable powerful health promotion targeted at people at risk and to support people with long term conditions.

Serving millions of patients and thousands of healthcare professionals every day iPLATO has emerged as the leader in mobile health. Across this network the company is running campaigns to promote smoking cessation, weight loss, childhood immunisation and pandemic awareness as well as mobile disease management services for people with diabetes, hypertension, epilepsy and HIV.

iPLATO Healthcare's mission is to, in partnership with clinicians, help healthcare commissioners transform patient care through cloud based mHealth and Analytics.

Most Popular Now

Study Finds One-Year Change on CT Scans …

Researchers at National Jewish Health have shown that subtle increases in lung scarring, detected by an artificial intelligence-based tool on CT scans taken one year apart, are associated with disease...

New AI Tools Help Scientists Track How D…

Artificial intelligence (AI) can solve problems at remarkable speed, but it’s the people developing the algorithms who are truly driving discovery. At The University of Texas at Arlington, data scientists...

Yousif's Story with Sectra and The …

Embarking on healthcare technology career after leaving his home as a refugee during his teenage years, Yousif is passionate about making a difference. He reflects on an apprenticeship in which...

AI Tool Offers Deep Insight into the Imm…

Researchers explore the human immune system by looking at the active components, namely the various genes and cells involved. But there is a broad range of these, and observations necessarily...

New Antibiotic Targets IBD - and AI Pred…

Researchers at McMaster University and the Massachusetts Institute of Technology (MIT) have made two scientific breakthroughs at once: they not only discovered a brand-new antibiotic that targets inflammatory bowel diseases...

Highland to Help Companies Seize 'N…

Health tech growth partner Highland has today revealed its new identity - reflecting a sharper focus as it helps health tech companies to find market opportunities, convince target audiences, and...